Mineralocorticoid receptor antagonists can not only lower blood pressure, but also improve insulin sensitivity, relieve oxidative stress and reduce the inflammatory response of MetS, which could eventually prevent the occurrence of cardiovascular disease (26). The gene discussed is NR3C2; the disease is metabolic syndrome.